SDF-1(5-67) neutralizing antibody enhances hippocampal neurogenesis and rescues cognitive deficits in chronic temporal lobe epilepsy.

ABSTRACT: Cognitive impairment is a debilitating comorbidity in temporal lobe epilepsy (TLE), linked to suppressed hippocampal neurogenesis in the chronic phase. Building on evidence that links SDF-1 to epilepsy, emerging research, including our own preliminary data, suggests that its cleaved product, SDF-1(5-67), may play a critical role in this process. To investigate the therapeutic potential of SDF-1(5-67) neutralizing antibody (NAb) in a kainic acid (KA)-induced temporal lobe epilepsy (TLE) model. TLE was induced in male Wistar rats by intraventricular KA injection. Animals were divided into acute (8 days) and chronic (72 days) phase groups, including acute phase control (SHAM-A), acute phase epilepsy model (EP-A), SDF-1(5-67) NAb-treated acute phase epilepsy (S + EP-A), chronic phase control (

SUBMITTER: Ma XY 

PROVIDER: S-EPMC12823598 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature